ID   FXR1_RAT                Reviewed;         568 AA.
AC   Q5XI81;
DT   05-SEP-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 1.
DT   02-OCT-2024, entry version 127.
DE   RecName: Full=RNA-binding protein FXR1 {ECO:0000305};
DE   AltName: Full=FMR1 autosomal homolog 1 {ECO:0000312|RGD:1311733};
GN   Name=Fxr1 {ECO:0000312|RGD:1311733};
GN   Synonyms=Fxr1h {ECO:0000312|EMBL:AAH83807.1};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-398; SER-432; SER-435;
RP   SER-438; SER-449; SER-452; THR-512 AND SER-514, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: mRNA-binding protein that acts as a regulator of mRNAs
CC       translation and/or stability, and which is required for various
CC       processes, such as neurogenesis, muscle development and
CC       spermatogenesis. Specifically binds to AU-rich elements (AREs) in the
CC       3'-UTR of target mRNAs. Promotes formation of some phase-separated
CC       membraneless compartment by undergoing liquid-liquid phase separation
CC       upon binding to AREs-containing mRNAs, leading to assemble mRNAs into
CC       cytoplasmic ribonucleoprotein granules that concentrate mRNAs with
CC       associated regulatory factors. Required to activate translation of
CC       stored mRNAs during late spermatogenesis: acts by undergoing liquid-
CC       liquid phase separation to assemble target mRNAs into cytoplasmic
CC       ribonucleoprotein granules that recruit translation initiation factor
CC       EIF4G3 to activate translation of stored mRNAs in late spermatids (By
CC       similarity). Promotes translation of MYC transcripts by recruiting the
CC       eIF4F complex to the translation start site. Acts as a negative
CC       regulator of inflammation in response to IL19 by promoting
CC       destabilization of pro-inflammatory transcripts (By similarity). Also
CC       acts as an inhibitor of inflammation by binding to TNF mRNA, decreasing
CC       TNF protein production. Acts as a negative regulator of AMPA receptor
CC       GRIA2/GluA2 synthesis during long-lasting synaptic potentiation of
CC       hippocampal neurons by binding to GRIA2/GluA2 mRNA, thereby inhibiting
CC       its translation. Regulates proliferation of adult neural stem cells by
CC       binding to CDKN1A mRNA and promoting its expression. Acts as a
CC       regulator of sleep and synaptic homeostasis by regulating translation
CC       of transcripts in neurons. Required for embryonic and postnatal
CC       development of muscle tissue by undergoing liquid-liquid phase
CC       separation to assemble target mRNAs into cytoplasmic ribonucleoprotein
CC       granules (By similarity). Involved in the nuclear pore complex
CC       localization to the nuclear envelope by preventing cytoplasmic
CC       aggregation of nucleoporins: acts by preventing ectopic phase
CC       separation of nucleoporins in the cytoplasm via a microtubule-dependent
CC       mechanism (By similarity). Plays a role in the stabilization of PKP2
CC       mRNA and therefore protein abundance, via its interaction with PKP3 (By
CC       similarity). May also do the same for PKP2, PKP3 and DSP via its
CC       interaction with PKP1 (By similarity). {ECO:0000250|UniProtKB:P51114,
CC       ECO:0000250|UniProtKB:Q61584}.
CC   -!- SUBUNIT: Interacts with FMR1. Interacts with FRX2. Interacts with
CC       TDRD3. Interacts with HABP4 (By similarity). Interacts with CYFIP2 but
CC       not with CYFIP1. Interacts with EIF4G3; promoting translation of target
CC       mRNAs (By similarity). Interacts with ELAVL1. Interacts with CEP63;
CC       inhibiting 'Lys-63'-linked ubiquitination (By similarity). Interacts
CC       with PKP3; the interaction facilitates the binding of PKP3 to PKP2 mRNA
CC       (By similarity). Interacts with PKP1; the interaction may facilitate
CC       the binding of PKP1 to PKP2, PKP3 and DSP mRNA (By similarity).
CC       {ECO:0000250|UniProtKB:P51114, ECO:0000250|UniProtKB:Q61584}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, Cytoplasmic ribonucleoprotein granule
CC       {ECO:0000250|UniProtKB:Q61584}. Cytoplasm, Stress granule
CC       {ECO:0000250|UniProtKB:P51114}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q61584}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q61584}. Cell projection, dendritic spine
CC       {ECO:0000250|UniProtKB:Q61584}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q61584}. Nucleus envelope
CC       {ECO:0000250|UniProtKB:P51114}. Postsynapse
CC       {ECO:0000250|UniProtKB:Q61584}. Note=Specifically localizes to
CC       cytoplasmic ribonucleoprotein membraneless compartments (By
CC       similarity). Localizes to stress granules following phosphorylation at
CC       Ser-449 by PAK1 (By similarity). Adjacent to Z-lines in muscles (By
CC       similarity). {ECO:0000250|UniProtKB:P51114,
CC       ECO:0000250|UniProtKB:Q61584}.
CC   -!- DOMAIN: Disordered region at the C-terminus undergoes liquid-liquid
CC       phase separation (LLPS) for the formation of a membraneless compartment
CC       that stores mRNAs. {ECO:0000250|UniProtKB:Q61584}.
CC   -!- DOMAIN: The tandem Agenet-like domains preferentially recognize
CC       trimethylated histone peptides. {ECO:0000250|UniProtKB:P51114}.
CC   -!- PTM: Phosphorylation at Ser-449 by PAK1 promotes its relocalization to
CC       stress granules and activity (By similarity). Phosphorylated by
CC       MAPK1/ERK2, promoting subsequent phosphorylation by GSK3B.
CC       Phosphorylated by GSK3B, promoting ubiquitination and degradation by
CC       the proteasome (By similarity). {ECO:0000250|UniProtKB:P51114,
CC       ECO:0000250|UniProtKB:Q61584}.
CC   -!- PTM: Ubiquitinated by the SCF(FBXO4) complex, leading to its
CC       degradation by the proteasome: ubiquitination by the SCF(FBXO4) complex
CC       takes place following phosphorylation by GSK3B. Ubiquitinated and
CC       degraded in a GSK3B-dependent manner in during both scaling and sleep
CC       deprivation (By similarity). Ubiquitinated via 'Lys-63'-linked
CC       ubiquitin, leading to its degradation: interaction with CEP63 inhibits
CC       'Lys-63'-linked ubiquitination (By similarity).
CC       {ECO:0000250|UniProtKB:P51114, ECO:0000250|UniProtKB:Q61584}.
CC   -!- MISCELLANEOUS: This protein corresponds to isoform B in mouse and
CC       isoform 2 in human. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the FMR1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC083807; AAH83807.1; -; mRNA.
DR   RefSeq; NP_001012179.1; NM_001012179.2.
DR   AlphaFoldDB; Q5XI81; -.
DR   SMR; Q5XI81; -.
DR   BioGRID; 263063; 2.
DR   IntAct; Q5XI81; 4.
DR   MINT; Q5XI81; -.
DR   STRING; 10116.ENSRNOP00000069834; -.
DR   BindingDB; Q5XI81; -.
DR   iPTMnet; Q5XI81; -.
DR   PhosphoSitePlus; Q5XI81; -.
DR   jPOST; Q5XI81; -.
DR   PaxDb; 10116-ENSRNOP00000065667; -.
DR   GeneID; 361927; -.
DR   KEGG; rno:361927; -.
DR   UCSC; RGD:1311733; rat.
DR   AGR; RGD:1311733; -.
DR   CTD; 8087; -.
DR   RGD; 1311733; Fxr1.
DR   eggNOG; ENOG502QPKJ; Eukaryota.
DR   InParanoid; Q5XI81; -.
DR   OrthoDB; 2995592at2759; -.
DR   PhylomeDB; Q5XI81; -.
DR   PRO; PR:Q5XI81; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030424; C:axon; ISO:RGD.
DR   GO; GO:0043034; C:costamere; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; ISS:UniProtKB.
DR   GO; GO:0010494; C:cytoplasmic stress granule; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005635; C:nuclear envelope; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0098794; C:postsynapse; ISO:RGD.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0035770; C:ribonucleoprotein granule; ISO:RGD.
DR   GO; GO:0005840; C:ribosome; ISO:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISS:UniProtKB.
DR   GO; GO:0035925; F:mRNA 3'-UTR AU-rich region binding; ISS:UniProtKB.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; ISO:RGD.
DR   GO; GO:0003729; F:mRNA binding; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; ISO:RGD.
DR   GO; GO:0003723; F:RNA binding; ISO:RGD.
DR   GO; GO:0033592; F:RNA strand annealing activity; ISS:UniProtKB.
DR   GO; GO:0045182; F:translation regulator activity; IBA:GO_Central.
DR   GO; GO:0048513; P:animal organ development; IBA:GO_Central.
DR   GO; GO:0021542; P:dentate gyrus development; ISS:UniProtKB.
DR   GO; GO:0061157; P:mRNA destabilization; ISS:UniProtKB.
DR   GO; GO:0051028; P:mRNA transport; IBA:GO_Central.
DR   GO; GO:0007517; P:muscle organ development; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; ISS:UniProtKB.
DR   GO; GO:1902373; P:negative regulation of mRNA catabolic process; ISO:RGD.
DR   GO; GO:0017148; P:negative regulation of translation; ISS:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISS:UniProtKB.
DR   GO; GO:0140694; P:non-membrane-bounded organelle assembly; ISS:UniProtKB.
DR   GO; GO:0051292; P:nuclear pore complex assembly; ISS:UniProtKB.
DR   GO; GO:0051664; P:nuclear pore localization; ISS:UniProtKB.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IBA:GO_Central.
DR   GO; GO:2000637; P:positive regulation of miRNA-mediated gene silencing; ISS:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; ISS:UniProtKB.
DR   GO; GO:0010608; P:post-transcriptional regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0045187; P:regulation of circadian sleep/wake cycle, sleep; ISS:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; IBA:GO_Central.
DR   GO; GO:0050767; P:regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; ISS:UniProtKB.
DR   GO; GO:0099577; P:regulation of translation at presynapse, modulating synaptic transmission; IBA:GO_Central.
DR   GO; GO:0060538; P:skeletal muscle organ development; ISO:RGD.
DR   GO; GO:0007286; P:spermatid development; ISS:UniProtKB.
DR   CDD; cd22504; KH_I_FXR1_rpt1; 1.
DR   CDD; cd22507; KH_I_FXR1_rpt2; 1.
DR   CDD; cd22510; KH_I_FXR1_rpt3; 1.
DR   CDD; cd20472; Tudor_Agenet_FXR1_rpt1; 1.
DR   CDD; cd20475; Tudor_Agenet_FXR1_rpt2; 1.
DR   Gene3D; 2.30.30.140; -; 2.
DR   Gene3D; 3.30.1370.10; K Homology domain, type 1; 2.
DR   InterPro; IPR008395; Agenet-like_dom.
DR   InterPro; IPR040148; FMR1.
DR   InterPro; IPR022034; FMR1-like_C_core.
DR   InterPro; IPR040472; FMRP_KH0.
DR   InterPro; IPR032172; FXR1_C1.
DR   InterPro; IPR004087; KH_dom.
DR   InterPro; IPR004088; KH_dom_type_1.
DR   InterPro; IPR036612; KH_dom_type_1_sf.
DR   InterPro; IPR047494; KH_I_FXR1_rpt1.
DR   InterPro; IPR047495; KH_I_FXR1_rpt2.
DR   InterPro; IPR047496; KH_I_FXR1_rpt3.
DR   InterPro; IPR047425; Tudor_Agenet_FXR1_rpt1.
DR   InterPro; IPR047427; Tudor_Agenet_FXR1_rpt2.
DR   InterPro; IPR041560; Tudor_FRM1.
DR   PANTHER; PTHR10603; FRAGILE X MENTAL RETARDATION SYNDROME-RELATED PROTEIN; 1.
DR   PANTHER; PTHR10603:SF6; FRAGILE X MENTAL RETARDATION SYNDROME-RELATED PROTEIN 1; 1.
DR   Pfam; PF05641; Agenet; 1.
DR   Pfam; PF12235; FXMRP1_C_core; 1.
DR   Pfam; PF16096; FXR_C1; 1.
DR   Pfam; PF00013; KH_1; 2.
DR   Pfam; PF17904; KH_9; 1.
DR   Pfam; PF18336; Tudor_FRX1; 1.
DR   SMART; SM00322; KH; 2.
DR   SUPFAM; SSF54791; Eukaryotic type KH-domain (KH-domain type I); 2.
DR   PROSITE; PS51641; AGENET_LIKE; 2.
DR   PROSITE; PS50084; KH_TYPE_1; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Cell projection; Cytoplasm; Developmental protein;
KW   Differentiation; Isopeptide bond; Methylation; Myogenesis; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; RNA-binding; Spermatogenesis;
KW   Synapse; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P51114"
FT   CHAIN           2..568
FT                   /note="RNA-binding protein FXR1"
FT                   /id="PRO_0000248488"
FT   DOMAIN          4..50
FT                   /note="Agenet-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00973"
FT   DOMAIN          63..115
FT                   /note="Agenet-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00973"
FT   DOMAIN          218..279
FT                   /note="KH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00117"
FT   DOMAIN          281..351
FT                   /note="KH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00117"
FT   REGION          380..568
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          471..486
FT                   /note="RNA-binding RGG-box"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        438..473
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        496..518
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P51114"
FT   MOD_RES         68
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61584"
FT   MOD_RES         398
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         430
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P51114"
FT   MOD_RES         432
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         435
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         476
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35922"
FT   MOD_RES         476
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35922"
FT   MOD_RES         482
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35922"
FT   MOD_RES         482
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35922"
FT   MOD_RES         484
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35922"
FT   MOD_RES         484
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35922"
FT   MOD_RES         512
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         514
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         553
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P51116"
FT   CROSSLNK        56
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P51114"
SQ   SEQUENCE   568 AA;  63947 MW;  C6FBCD4F23B248AF CRC64;
     MAELTVEVRG SNGAFYKVFI KDVHEDSLTV VFENNWQPER QVPFNEVRLP PPPDIKKEIS
     EGDEVEVYSR ANDQEPCGWW LAKVRMMKGE FYVIEYAACD ATYNEIVTFE RLRPVNQNKT
     VKKNTFFKCT VDVPEDLREA CANENAHKDF KKAVGACRIF YHPETTQLMI LSASEATVKR
     VNILSDMHLR SIRTKLMLMS RNEEATKHLE CTKQLAAAFH EEFVVREDLM GLAIGTHGSN
     IQQARKVPGV TAIELDEDTG TFRIYGESAE AVKKARGFLE FVEDFIQVPR NLVGKVIGKN
     GKVIQEIVDK SGVVRVRIEG DNENKLPRED GMVPFVFVGT KESIGNVQVL LEYHIAYLKE
     VEQLRMERLQ IDEQLRQIGM GFRPSSTRGP EKEKGYATDE STVSSVQGSR SYSGRGRGRR
     GPNYTSGYGT NSELSNPSET ESERKDELSD WSLAGEDDRE TRHQRDSRRR PGGRGRSVSG
     GRGRGGPRGG KSSISSVLKD PDSNPYSLLD NTESDQTADT DASESHHSTN RRRRSRRRRT
     DEDAVLMDGM TESDTASVNE NGLGKRCD
//
